greeksoup/ stock research

Kimball Electronics, Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 4 February 2026: press release. Guidance figures: 2 raised, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue fell 5% year over year: Net sales were $341.3 million, down 5% from $357.4 million a year earlier. Constant currency growth was down 7%, with foreign currency adding 2 points. Source
  • Sales guidance range raised: Fiscal 2026 net sales guidance is $1,400 to $1,460 million, up from $1,350 to $1,450 million. Source
  • Adjusted margin guidance raised: Fiscal 2026 adjusted operating income is now estimated at 4.2% to 4.5% of net sales, up from 4.0% to 4.25%. Source
  • Medical sales up 15%: Medical sales were $96.3 million, up 15% from $84.0 million, and 28% of net sales. Source
  • Open orders fell to $557 million: Open orders were $557 million, against $593 million at September 30, 2025 and $564 million at December 31, 2024. Source
  • Gross margin rose to 8.2%: Gross profit was $27.9 million, or 8.2% of net sales, against $23.4 million, or 6.6%, a year earlier. Source
  • Rebrand to Kimball Solutions: The company announced a rebrand as Kimball Solutions. Management said the rebrand and the Indianapolis facility reflect its medical strategy and expanded offering. Source

“I’m pleased with the results for the second quarter and our updated guidance for fiscal 2026.”

Richard D. Phillips Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Net sales SourceFiscal 2026$1,400 - $1,460 millionRaised from $1,350 - $1,450 million
Adjusted operating income as % of net sales SourceFiscal 20264.2% - 4.5%Raised from 4.0% - 4.25%
Capital expenditures SourceFiscal 2026$50 - $60 millionKept

What changed from last quarter

  • Guidance raised: Fiscal 2026 net sales guidance was raised: the low end rose $50 million and the high end rose $10 million. Source
  • Guidance raised: Fiscal 2026 adjusted operating income guidance was raised to 4.2% to 4.5% of net sales. Source
  • Guidance kept: Capital expenditure guidance was unchanged at $50 to $60 million. Source
  • New: The company announced a rebrand as Kimball Solutions. The prior quarter's release did not mention it. Source
  • New: A new medical manufacturing facility in Indianapolis held its grand opening. Source

Results and growth drivers

  • Revenue fell 5% year over year: Net sales were $341.3 million, down 5% from $357.4 million a year earlier. Constant currency growth was down 7%, with foreign currency adding 2 points. Source
  • Operating margin rose to 3.2%: Operating income was $10.8 million, or 3.2% of net sales, against $8.2 million, or 2.3%, a year earlier. Diluted EPS was $0.15, against $0.14. Source
  • Adjusted margin up 80 basis points: Adjusted operating income was 4.5% of net sales, up 80 basis points. Adjusted diluted EPS was $0.28, against $0.29 a year earlier. Source
  • Year-to-date sales down 3%: Six-month net sales were $706.9 million, down 3%. Six-month diluted EPS was $0.55, against $0.26 a year earlier. Source

Fiscal 2026 guidance

  • Sales guidance range raised: Fiscal 2026 net sales guidance is $1,400 to $1,460 million, up from $1,350 to $1,450 million. Source
  • Adjusted margin guidance raised: Fiscal 2026 adjusted operating income is now estimated at 4.2% to 4.5% of net sales, up from 4.0% to 4.25%. Source
  • Capital spending guidance unchanged: Fiscal 2026 capital expenditure guidance remains $50 to $60 million. Source

“Our focus as a medical CMO continues to gain momentum as we leverage our unique capabilities in the industry.”

Richard D. Phillips Chief Executive Officer

Verticals and demand

  • Medical sales up 15%: Medical sales were $96.3 million, up 15% from $84.0 million, and 28% of net sales. Source
  • Automotive sales down 13%: Automotive sales were $162.3 million, down 13% from $186.3 million, and 48% of net sales. Source
  • Industrial sales down 5%: Industrial excluding AT&M sales were $82.7 million, down 5% from $87.1 million. Commercial transportation moved into industrial in fiscal 2026, with prior periods recast. Source
  • Open orders fell to $557 million: Open orders were $557 million, against $593 million at September 30, 2025 and $564 million at December 31, 2024. Source

Gross margin and costs

  • Gross margin rose to 8.2%: Gross profit was $27.9 million, or 8.2% of net sales, against $23.4 million, or 6.6%, a year earlier. Source
  • Selling and admin costs up: Selling and administrative expenses were $14.9 million, or 4.4% of net sales, against $10.5 million. Stock compensation expense was $2.2 million, against $0.5 million. Source
  • Restructuring costs lower: Restructuring expense was $1.8 million, against $4.7 million a year earlier. A $0.4 million asset impairment was also recorded. Source
  • Interest expense lower: Interest expense was $2.1 million, down from $4.2 million a year earlier. Source

“We expect top-line growth in medical to outpace our other two verticals as we balance our portfolio across the markets we serve.”

Richard D. Phillips Chief Executive Officer

Cash, debt and share repurchases

  • Operating cash flow positive again: Cash from operations was $6.9 million, the eighth consecutive quarter of positive operating cash generation. Six-month operating cash flow was $14.9 million. Source
  • Cash conversion days improved year over year: Cash conversion days were 91, down 16 days from 107 a year earlier, and up from 83 in the prior quarter. Source
  • Debt rose to $154.2 million: Debt was $154.2 million, up from $138.0 million at the end of the first quarter. Borrowing capacity was $285.1 million. Source
  • Share repurchases stepped up: The company repurchased 149,000 shares for $4.3 million, against 49,000 shares for $1.5 million in the first quarter. Source

Strategy and medical focus

  • Rebrand to Kimball Solutions: The company announced a rebrand as Kimball Solutions. Management said the rebrand and the Indianapolis facility reflect its medical strategy and expanded offering. Source
  • Indianapolis medical plant opened: A new medical manufacturing facility in Indianapolis held its grand opening. Source
  • Medical CMO focus gaining momentum: Management said its medical CMO focus is gaining momentum, drawing on capabilities it describes as unique in the industry. Source

Figures management reported

FigureReported
Backlog (open orders) Source$557 million
Gross margin Source8.2%
Medical end-market revenue Source$96.3 million
Automotive end-market revenue Source$162.3 million
Industrial end-market revenue Source$82.7 million

Earlier plans management reported on

  • Met: Management said second-quarter sales were in line with expectations. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.